Study Shows Improved Survival in Aggressive Acute Myeloid Leukemia
University of Texas MD Anderson Cancer CenterPatients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.